Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Rezolute To Contact Him Directly To Discuss Their Options If you suffered significant losses in Rezolute stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a l ...

Company believes that data from sunRIZE and the Expanded Access Program (EAP) provide evidence of activity of ersodetug in both indications Company plans to meet with FDA to align on path forward for congenital HI REDWOOD CITY, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today shared observations from the Phase 3 sunRIZE study in patients ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Rezolute To Contact Him Directly To Discuss Their Options If you suffered significant losses in Rezolute stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Jan. 03, 2026 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a l ...

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Rezolute, Inc. and its officers or directors following disappointing clinical trial results that led to a significant drop in the company's stock price [1][3]. Group 1: Company Overview - Rezolute, Inc. is a publicly traded company on NASDAQ under the ticker RZLT [1]. - The company recently announced topline results from its Phase 3 sunRIZE study evaluating ersodetug for congenital hyperinsulinism [3]. Group 2: Clinical Trial Results - The Phase 3 study did not meet its primary endpoint, which was to assess the change in average weekly hypoglycemia events, showing only a 45% reduction in events at the highest dose of ersodetug (10 mg/kg), which was not statistically significant compared to a 40% improvement in the placebo group [3]. - The study also failed to meet its key secondary endpoint, with a 25% reduction in average daily percent time in hypoglycemia at the 10 mg/kg dose, again not statistically significant compared to a 5% increase in the placebo group [3]. Group 3: Stock Market Reaction - Following the announcement of the clinical trial results, Rezolute's stock price fell by $9.44 per share, or 87.2%, closing at $1.77 per share on December 19, 2025 [3].

On December 24, Jared Holz of Mizuho joined ‘Power Lunch’ on CNBC to talk about how to play biotech moving into 2026. Holz noted that healthcare has become the top-performing sector over the last 3 months as investors rotate away from high-valuation tech and AI stocks. Despite this recent run, he argued that the sector has room to continue its upward trajectory, pointing out that it was a multi-year laggard, trailing the S&P 500 by 20% in 2023 and roughly 5% in 2024. He described the current rotation as a c ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses in Rezolute to Contact Him Directly to Discuss Their OptionsIf you suffered significant losses in Rezolute stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. - December 29, 2025) - Faruqi & Far ...

Core Insights - Rezolute, Inc. experienced a significant decline in its stock price following disappointing results from its Phase 3 sunRIZE clinical trial for its lead drug candidate, ersodetug, which failed to meet primary and key secondary endpoints [4][5] Group 1: Company Overview - Rezolute, Inc. is publicly traded on NASDAQ under the ticker RZLT [2] - The company is focused on developing treatments for congenital hyperinsulinism [4] Group 2: Clinical Trial Results - The Phase 3 sunRIZE clinical trial for ersodetug did not achieve statistically significant reductions in hypoglycemia events compared to placebo [4] - The highest dose in the trial showed reductions that were not statistically significant [4] Group 3: Stock Performance - On December 11, 2025, Rezolute's stock price plummeted from approximately $10.94 to an intraday low of around $0.90, marking an approximate 85-90% drop [5] - Trading was halted under Nasdaq's volatility controls due to the drastic decline [5]

Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. SOURCE Faruqi & Faruqi, LLP Rezolute, Inc. shares tumbled sharply on December 11, 2025, as investors reacted to disappointin ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Rezolute To Contact Him Directly To Discuss Their Options If you suffered significant losses in Rezolute stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) --  Faruqi & Faruqi, LLP, a ...

Key Takeaways Rezolute stock plunged after phase III data showed ersodetug failed to meet the primary goal in the HI study.RZLT's top dose cut HI events ~45%, but placebo improved ~40%, leaving results not statistically significant.RZLT is reviewing data, planning FDA talks, and advancing ersodetug in tumor-induced HI via the upLIFT study.Shares of Rezolute (RZLT) have plummeted 79.2% so far in December. The massive stock price crash was observed after RZLT reported disappointing top-line data from a late-s ...